The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Open accessAbstract
Cancer is one of the main causes of death worldwide. Despite the significant development of methods of cancer healing during the past decades, chemotherapy still remains the main method for cancer treatment. Depending on the mechanism of action, commonly used chemotherapeutic agents can be divided into several classes (antimetabolites, alkylating agents, mitotic spindle inhibitors, topoisomerase inhibitors, and others). Multidrug resistance (MDR) is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutics or novel targeted drugs. The mechanisms of MDR include elevated metabolism of xenobiotics, enhanced efflux of drugs, growth factors, increased DNA repair capacity, and genetic factors (gene mutations, amplifications, and epigenetic alterations). Rapidly increasing numbers of biomedical studies are focused on designing chemotherapeutics that are able to evade or reverse MDR. The aim of this review is not only to demonstrate the latest data on the mechanisms of cellular resistance to anticancer agents currently used in clinical treatment but also to present the mechanisms of action of novel potential antitumor drugs which have been designed to overcome these resistance mechanisms. Better understanding of the mechanisms of MDR and targets of novel chemotherapy agents should provide guidance for future research concerning new effective strategies in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, L., Li, X., Cheng, M., Wang, S., Zheng, Q., & Liu, Q. (2018) · RSC Advances · doi:10.1039/c8ra09506j · Cited by 11
RetractedGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Fitzmaurice, C., & Global Burden of Disease Cancer Collaboration (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1568 · Cited by 1,646
Glutathione metabolism in cancer progression and treatment resistance
Bansal, A., & Simon, M. C. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201804161 · Cited by 1,233
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Wu, Q., Yang, Z., Nie, Y., Shi, Y., & Fan, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.013 · Cited by 776
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Mechanisms of Drug Resistance in Cancer Chemotherapy
Luqmani, Y. A. (2005) · Medical Principles and Practice · doi:10.1159/000086183 · Cited by 651
Analysis of anticancer drugs: A review
Nussbaumer, S., Bonnabry, P., Veuthey, J.-L., & Fleury-Souverain, S. (2011) · Talanta · doi:10.1016/j.talanta.2011.08.034 · Cited by 568
Epigenetic modifications of histones in cancer
Zhao, Z., & Shilatifard, A. (2019) · Genome Biology · doi:10.1186/s13059-019-1870-5 · Cited by 552
Epigenetic modifications in cancer
Kanwal, R., & Gupta, S. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01809.x · Cited by 550
FDA Drug Approval Summary: Azacitidine (5-azacytidine, Vidaza™) for Injectable Suspension
Kaminskas, E., Farrell, A. T., Wang, Y.-C., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-3-176 · Cited by 490
Anticancer Activity of Natural Compounds from Plant and Marine Environment
Lichota, A., & Gwozdzinski, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113533 · Cited by 473
DNA repair pathways and cisplatin resistance: an intimate relationship
Rocha, C. R. R., Silva, M. M., Quinet, A., Cabral-Neto, J. B., & Menck, C. F. M. (2018) · Clinics · doi:10.6061/clinics/2018/e478s · Cited by 446
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
Jiang, D., He, Z., Wang, C., Zhou, Y., Li, F., Pu, W., Zhang, X., Feng, X., Zhang, M., Yecheng, X., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-1236-z · Cited by 372
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Fok, J. H. L., Ramos-Montoya, A., Vazquez-Chantada, M., Wijnhoven, P. W. G., Follia, V., James, N., Farrington, P. M., Karmokar, A., Willis, S. E., Cairns, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12836-9 · Cited by 331
Unraveling the Potential Role of Glutathione in Multiple Forms of Cell Death in Cancer Therapy
Lv, H., Zhen, C., Liu, J., Yang, P., Hu, L., & Shang, P. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3150145 · Cited by 320
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
Elgendy, M., Cirò, M., Hosseini, A., Weiszmann, J., Mazzarella, L., Ferrari, E., Cazzoli, R., Curigliano, G., DeCensi, A., Bonanni, B., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.007 · Cited by 299
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 289
Nanayakkara, A. K., Follit, C. A., Chen, G., Williams, N. S., Vogel, P. D., & Wise, J. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19325-x · Cited by 282
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
Conze, D. B., Weiss, L., Regen, P. S., Bhushan, A., Weaver, D. L., Johnson, P. F., & Rincón, M. (2001) · PubMed · Cited by 280
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
Ham, I.-H., Oh, H. J., Jin, H., Bae, C. A., Jeon, S.-M., Choi, K. S., Son, S.-Y., Han, S.-U., Brekken, R. A., Lee, D., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0972-8 · Cited by 264
Vendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 239
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Setrerrahmane, S., & Xu, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0721-9 · Cited by 237
Wang, Z., Wang, N., Liu, P., Chen, Q., Situ, H., Xie, T., Zhang, J., Peng, C., Lin, Y., & Chen, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2192 · Cited by 224
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L., & Chandarlapaty, S. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0001-z · Cited by 216
Novel strategies to prevent the development of multidrug resistance (MDR) in cancer
Wang, J., Seebacher, N., Shi, H., Kan, Q., & Duan, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.19187 · Cited by 207
Targeting DNA Repair Pathways for Cancer Treatment: what’s new?
Kelley, M. R., Logsdon, D., & Fishel, M. L. (2014) · Future Oncology · doi:10.2217/fon.14.60 · Cited by 202
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199
Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs
Song, S., Wientjes, M. G., Gan, Y., & Au, J. L.-S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.140210697 · Cited by 195
A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy
Wojtaszek, J. L., Chatterjee, N., Najeeb, J., Ramos, A., Lee, M., Bian, K., Xue, J. Y., Fenton, B. A., Park, H., Li, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.028 · Cited by 194
miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1
Shang, Y., Zhang, Z., Liu, Z., Feng, B., Ren, G., Li, K., Zhou, L., Sun, Y., Li, M., Zhou, J., et al. (2014) · Oncogene · doi:10.1038/onc.2013.297 · Cited by 188
Duesberg, P., Stindl, R., & Hehlmann, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14295 · Cited by 165
Mattos‐Arruda, L. D., Bottai, G., Nuciforo, P. G., Tommaso, L. D., Giovannetti, E., Peg, V., Losurdo, A., Pérez-García, J. M., Masci, G., Corsi, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5495 · Cited by 159
Targeting Glutathione Metabolism: Partner in Crime in Anticancer Therapy
Desideri, E., Ciccarone, F., & Ciriolo, M. R. (2019) · Nutrients · doi:10.3390/nu11081926 · Cited by 157
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
Lal, S., Wong, Z. W., Sandanaraj, E., Xiang, X., Ang, P., Lee, E. J. D., & Chowbay, B. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00744.x · Cited by 137
DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion
Bax, B. D., Murshudov, G. N., Maxwell, A., & Germe, T. R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.07.008 · Cited by 134
Erastin decreases radioresistance of NSCLC cells partially by inducing GPX4‑mediated ferroptosis
Pan, X., Lin, Z., Jiang, D., Yu, Y., Yang, D., Zhou, H., Zhan, D., Liu, S., Peng, G., Chen, Z., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.9888 · Cited by 130
Glutathione S-conjugates as prodrugs to target drug-resistant tumors
Ramsay, E. E., & Dilda, P. J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00181 · Cited by 129
Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death
Catanzaro, D., Gaude, E., Orso, G., Giordano, C., Guzzo, G., Rasola, A., Ragazzi, E., Caparrotta, L., Frezza, C., & Montopoli, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4945 · Cited by 129
Drug metabolizing enzymes and their inhibitors' role in cancer resistance
Pathania, S., Bhatia, R., Baldi, A., Singh, R., & Rawal, R. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.117 · Cited by 126
Role of extracellular matrix in breast cancer development: a brief update
Jena, M. K., & Janjanam, J. (2018) · F1000Research · doi:10.12688/f1000research.14133.1 · Cited by 118
Fibroblast Growth Factor Receptor Functions in Glioblastoma
Jimenez‐Pascual, A., & Siebzehnrübl, F. A. (2019) · Cells · doi:10.3390/cells8070715 · Cited by 118
Glutathione in Ovarian Cancer: A Double-Edged Sword
Nunes, S. C., & Serpa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071882 · Cited by 114
Patnaik, S., & Anupriya, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00588 · Cited by 112
Wang, Y., Qu, Y., Niu, X. L., Sun, W. J., Zhang, X. L., & Li, L. Z. (2011) · Cytokine · doi:10.1016/j.cyto.2011.06.005 · Cited by 110
Kikuchi, H., Yuan, B., Hu, X., & Okazaki, M. (2019) · PubMed · Cited by 109
Duesberg, P., Stindl, R., & Hehlmann, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398998 · Cited by 106
Zhu, J., Zou, Z., Nie, P., Kou, X., Wu, B., Wang, S., Song, Z., & He, J. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.361 · Cited by 106
Alagpulinsa, D. A., Ayyadevara, S., & Reis, R. J. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00289 · Cited by 105
Inoue, A., Kikuchi, S., Hishiki, A., Shao, Y., Heath, R. J., Evison, B. J., Actis, M. L., Canman, C. E., Hashimoto, H., & Fujii, N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.520429 · Cited by 102
Chen, S., Wu, J., Jiao, K., Wu, Q., Ma, J., Chen, D., Kang, J., Zhao, G., Shi, Y., Fan, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0950-x · Cited by 101
To, K. K. W., Leung, W. W., & Ng, S. S. M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.09.011 · Cited by 99
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide
Lagas, J. S., Fan, L., Wagenaar, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1321 · Cited by 97
Villablanca, J. G., Volchenboum, S. L., Cho, H., Kang, M. H., Cohn, S. L., Anderson, C. P., Marachelian, A., Groshen, S. G., Tsao-Wei, D. D., Matthay, K. K., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25994 · Cited by 96
Aromatase Inhibitors for Breast Cancer in Postmenopausal Women
Campos, S. M. (2004) · The Oncologist · doi:10.1634/theoncologist.9-2-126 · Cited by 95
Protein kinase C-α and the regulation of diverse cell responses
Singh, R. K., Kumar, S., Gautam, P. K., Tomar, M. S., Verma, P. K., Singh, S. P., Kumar, S., & Acharya, A. (2017) · BioMolecular Concepts · doi:10.1515/bmc-2017-0005 · Cited by 95
MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression
Fan, Z., Cui, H., Yu, H., Ji, Q., Kang, L., Han, B., Wang, J., Dong, Q., Li, Y., Yan, Z., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.1 · Cited by 93
Miners, J. O., Chau, N., Rowland, A., Burns, K., McKinnon, R. A., Mackenzie, P. I., Tucker, G. T., Knights, K., & Kichenadasse, G. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.002 · Cited by 90
Tormo, E., Ballester, S., Adam‐Artigues, A., Burgués, O., Alonso, E., Bermejo, B., Menéndez, S., Zazo, S., Madoz‐Gúrpide, J., Rovira, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41472-y · Cited by 89
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
Shimizu, T., LoRusso, P. M., Papadopoulos, K. P., Patnaik, A., Beeram, M., Smith, L. S., Rasco, D. W., Mays, T. A., Chambers, G., Ma, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0570 · Cited by 85
miRNA profiling in pancreatic cancer and restoration of chemosensitivity
Singh, S. P., Chitkara, D., Kumar, V., Behrman, S. W., & Mahato, R. I. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.008 · Cited by 83
MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells
Wang, W., Zhao, L., Wei, X., Wang, L., Liu, S., Yang, Y. P., Wang, F., Sun, G., Zhang, J., Ma, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep27641 · Cited by 83
Molecular predictors of response to chemotherapy in lung cancer
Rosell, R., Tarón, M., Ariza, A., et al. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.011 · Cited by 81
Albarakati, N., Abdel-Fatah, T. M. A., Doherty, R. E., Russell, R., Agarwal, D., Moseley, P. M., Perry, C., Arora, A., Alsubhi, N. H., Seedhouse, C., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.001 · Cited by 79
Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance
McNeil, E. M., Astell, K. R., Ritchie, A., Shave, S., Houston, D. R., Bakrania, P., Jones, H. M., Khurana, P., Wallace, C., Chapman, T., et al. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.002 · Cited by 79
Ferroptosis‐inducing agents enhance TRAIL‐induced apoptosis through upregulation of death receptor 5
Lee, Y., Lee, D., Jeong, S. Y., Park, S. H., Oh, S. C., Park, Y. S., Yu, J., Choudry, H. A., Bartlett, D. L., & Lee, Y. J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27456 · Cited by 74
Gioia, U., Francia, S., Cabrini, M., Brambillasca, S., Michelini, F., Jones-Weinert, C. W., & di Fagagna, F. D. (2019) · Scientific Reports · doi:10.1038/s41598-019-42892-6 · Cited by 74
MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression
Yan, J. Y., Jiang, J., Meng, X., Xiu, Y., & Zong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0307-1 · Cited by 73
Chen, Y., Song, Y., Mi, Y., Jin, H., Cao, J., Li, H., Han, L., Huang, T., Zhang, X., Ren, S., et al. (2020) · APOPTOSIS · doi:10.1007/s10495-019-01588-y · Cited by 69
He, P.-F., Zhou, J., Yao, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17241 · Cited by 65
Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin.
Yuan, Z., Shi, X., Qiu, Y., Jia, T., Yuan, X., Zou, Y., Liu, C., Yu, H., Yuan, Y., He, X., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5410 · Cited by 61
Li, Y., Steppi, A., Zhou, Y., Mao, F., Miller, P. C., He, M. M., Zhao, T., Sun, Q., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-04250-2 · Cited by 61
Mishra, A. K., Dormi, S. S., Turchi, A. M., Woods, D. S., & Turchi, J. J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.013 · Cited by 58
Chandrasekhar, C., Pasupuleti, S. K., & Sarma, P. V. G. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-38672-x · Cited by 58
Shih, Y. T., Cortes, J. E., & Kantarjian, H. M. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30087-0 · Cited by 58
Lü, L., Fang, J., Zhao, H., & Ma, X. (2015) · Biotechnology Letters · doi:10.1007/s10529-015-1941-y · Cited by 57
Ying, X., Wei, K., Lin, Z., Cui, Y., Ding, J., Chen, Y., & Xu, B. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000445642 · Cited by 56
Liu, X., Luo, X., Wu, Y., Xia, D., Chen, W., Fang, Z., Deng, J., Hao, Y., Yang, X., Zhang, T., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494004 · Cited by 56
Neher, T. M., Bodenmiller, D. M., Fitch, R. W., Jalal, S. I., & Turchi, J. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0303 · Cited by 53
Chen, H.-J., Chung, Y.-L., Li, C.-Y., Chang, Y., Wang, C. C. N., Lee, H.-Y., Lin, H., & Hung, C. (2018) · Molecules · doi:10.3390/molecules23123055 · Cited by 53
Sail, V., Rizzo, A. A., Chatterjee, N., Dash, R. C., Ozen, Z., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01144 · Cited by 52
Wu, C., Hsiao, S.-H., Huang, Y.-H., Hung, L.-C., Yu, Y.-J., Chang, Y., Hung, T., & Wu, Y. (2020) · Cancers · doi:10.3390/cancers12010195 · Cited by 51
Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells
Kim, S. A., Kim, I. J., Yoon, S. K., Lee, E. K., & Kuh, H. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0528-9 · Cited by 48
MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer
Lin, H., Nikolić, I., Yang, J., Castillo, L. E., Deng, N., Chan, C., Yeung, N. K., Dodson, E., Elsworth, B., Spielman, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26050-y · Cited by 45
Pharmacogenomics and Histone Deacetylase Inhibitors
Goey, A. K. L., Sissung, T. M., Peer, C. J., & Figg, W. D. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0113 · Cited by 44
FBX8 degrades GSTP1 through ubiquitination to suppress colorectal cancer progression
FeiFei, W., Xu, H., YongRong, Y., Wu, P., Wu, J., XiaoHui, Z., Li, J., Sun, J., Kun, Z., Xiao-li, R., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1588-z · Cited by 40
Wahdan-Alaswad, R. S., Liu, B., & Thor, A. D. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.92 · Cited by 40
Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells
Guberović, I., Marjanović, M., Mioč, M., Ester, K., Martin‐Kleiner, I., Ramljak, T. Š., Mlinarić‐Majerski, K., & Kralj, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32770-y · Cited by 32
Computer‐aided drug design of small molecule inhibitors of the ERCC1‐XPF protein–protein interaction
Gentile, F., Elmenoufy, A. H., Ciniero, G., Jay, D., Karimi‐Busheri, F., Barakat, K., Weinfeld, M., West, F. G., & Tuszyński, J. A. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13660 · Cited by 32
Structure-Guided Optimization of Replication Protein A (RPA)–DNA Interaction Inhibitors
Gavande, N. S., VanderVere-Carozza, P. S., Pawelczak, K. S., Vernon, T. L., Jordan, M. R., & Turchi, J. J. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00440 · Cited by 30
de Souza, P. S., Madigan, J. P., Gillet, J., Kapoor, K., Ambudkar, S. V., Maia, R. C., Gottesman, M. M., & Fung, K. L. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.005 · Cited by 29
Osborne, M. J., de Oliveira, L. C., Volpon, L., Zahreddine, H. A., & Borden, K. L. B. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.11.007 · Cited by 29
Snyder, S., Murundi, S. D., Crawford, L., & Putnam, D. A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.027 · Cited by 29
Lara, L. I., Fenner, S., Ratcliffe, S. J., Isidro‐Llobet, A., Hann, M. M., Bax, B. D., & Osheroff, N. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky072 · Cited by 28
Amplification of the CD24 Gene Is an Independent Predictor for Poor Prognosis of Breast Cancer
Zhang, P., Zheng, P., & Liu, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00560 · Cited by 27
Peng, X., Li, L., Ren, Y., Xue, H., Liu, J., Wen, S., & Chen, J. (2020) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201901460 · Cited by 23
A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer
Evert, J., Pathak, S., Sun, X., & Zhang, H. (2018) · Journal of Cancer · doi:10.7150/jca.24474 · Cited by 21
Multiple roles of extracellular fibroblast growth factors in lung cancer cells
Suzuki, T., Yasuda, H., FUNAISHI, K., Arai, D., Ishioka, K., Ohgino, K., Tani, T., Hamamoto, J., Ohashi, A., Naoki, K., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2718 · Cited by 20
Reactive OFF-ON type alkylating agents for higher-ordered structures of nucleic acids
Onizuka, K., Hazemi, M. E., Sato, N., Tsuji, G.-I., Ishikawa, S., Ozawa, M., Tanno, K., Yamada, K., & Nagatsugi, F. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz512 · Cited by 20
The Effects of TiO2 Nanoparticles on Cisplatin Cytotoxicity in Cancer Cell Lines
Salama, B., El‐Sherbini, E., El‐Sayed, G., El‐Adl, M., Kanehira, K., & Taniguchi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020605 · Cited by 19
Okabe, S., Tanaka, Y., Moriyama, M., & Gotoh, A. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04022-x · Cited by 17
Inhibition of human erythrocyte glutathione S-transferase by some flavonoid derivatives
Aksoy, M., & Küfrevioğlu, İ. (2017) · Toxin Reviews · doi:10.1080/15569543.2017.1345945 · Cited by 16
The role of ABC transporters in anticancer drug transport
Karvar, S. (2014) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1407-3 · Cited by 13
Liu, Y., Zhang, L., Ma, Z., Li, T., Liu, Y., Liu, Y., Chen, Q., Li, Y., & Ma, E. (2019) · Free Radical Research · doi:10.1080/10715762.2019.1628957 · Cited by 12
Research works printed but not linked: 12
- Marchi, 2012, Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma, Ther. Adv. Hematol., 3, 227, 10.1177/2040620712445330 · doi:10.1177/2040620712445330
- Le, T., Bhushan, V., Sochat, M., and Chavda, Y. (2017). First Aid for the USMLE Step 1, McGraw-Hill Education. [1st ed.].
- Mesci, 2019, The effect of ATP-binding cassette (ABC) transporters in human cancers, Int. J. Sci. Lett., 1, 1, 10.38058/ijsl.594000 · doi:10.38058/ijsl.594000
- Zu, 2014, Effects of P-glycoprotein and its inhibitors on apoptosis in K562 cells, Molecules, 19, 13061, 10.3390/molecules190913061 · doi:10.3390/molecules190913061
- Satake, 2015, Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens, Biomed. Mater. Eng., 25, 249
- Galski, 2013, P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway, Biochem Pharmacol., 86, 584, 10.1016/j.bcp.2013.06.004 · doi:10.1016/j.bcp.2013.06.004
- Zhou, 2017, Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling, Oncotarget, 8, 101965, 10.18632/oncotarget.21949 · doi:10.18632/oncotarget.21949
- Greenfield, G., McMullan, R., Robson, N., McGimpsey, J., Catherwood, M., and McMullin, M.F. (2019). Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia. BMC Hematol., 19. · doi:10.1186/s12878-019-0139-2
- Lin, 2015, Upregulation of microRNA-224 sensitizes human cervical cells SiHa to paclitaxel, Eur. J. Gynaecol. Oncol., 36, 432
- Chapman, 2015, Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF, Bioorg. Med. Chem. Lett., 25, 4097, 10.1016/j.bmcl.2015.08.031 · doi:10.1016/j.bmcl.2015.08.031
- Wu, 2010, Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma, Invest. New Drugs, 28, 670, 10.1007/s10637-009-9286-9 · doi:10.1007/s10637-009-9286-9
- Demir, 2018, Evaluation of chalcones as inhibitors of glutathione S-transferase, J. Biochem. Mol. Toxicol., 32, e22047, 10.1002/jbt.22047 · doi:10.1002/jbt.22047
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02998-6 · Cited by 923
Regulated cell death (RCD) in cancer: key pathways and targeted therapies
Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., Chen, Y., & Han, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01110-y · Cited by 832
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Self-citationThe Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Metadata
- Authors
- Bukowski, K., Kciuk, M., & Kontek, R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-02
- Volume
- 21
- Issue
- 9
- Pages
- 3233
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3021909056
- Cited by
- 1,757
- References
- 115
- FWCI
- 66.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.